{"id":"NCT04279314","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome","officialTitle":"A 40-Week, Open-label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-29","primaryCompletion":"2022-08-19","completion":"2022-08-19","firstPosted":"2020-02-21","resultsPosted":"2024-04-11","lastUpdate":"2024-04-11"},"enrollment":154,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rett Syndrome"],"interventions":[{"type":"DRUG","name":"Trofinetide","otherNames":[]}],"arms":[{"label":"Trofinetide","type":"EXPERIMENTAL"}],"summary":"To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome","primaryOutcome":{"measure":"Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs), Percentage of Subjects With Serious Adverse Events (SAEs), and Percentage of Subjects With Withdrawals Due to AEs","timeFrame":"40 Weeks Treatment Duration","effectByArm":[{"arm":"Trofinetide","deltaMin":132,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":["38917793","37460385"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":154},"commonTop":["Diarrhoea","Vomiting","COVID-19","Upper respiratory tract infection","Pyrexia"]}}